United States Waldenstrom Macroglobulinemia Market Size, Share, Trends - Exclusive Report by DatamIntelligence

"Waldenstrom Macroglobulinemia market is estimated to reach at a high CAGR during the forecast period 2024-2031." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/waldenstrom-macroglobulinemia-market?sp

United States: Recent Industry Developments

✅ In July 2025, Cellectar Biosciences announced the US FDA granted Breakthrough Therapy Designation for iopofosine I 131 in Waldenstrom macroglobulinemia. This designation accelerates the development and review of this promising targeted radiopharmaceutical therapy. It highlights the growing focus on novel treatment options for WM.

✅ In June 2025, BeiGene presented encouraging Phase I/II results for BGB-16673 in Waldenstrom macroglobulinemia at the European Hematology Association 2025 meeting. The drug showed promising efficacy in patients with relapsed or refractory disease. This advance may offer new hope for treatment-resistant WM cases.

✅ In March 2025, the US FDA granted orphan drug designation to bexobrutideg (NX-5948) for WM treatment. This designation supports faster regulatory approval processes for this novel BTK degrader targeting WM. It underscores the importance of innovative therapies for this rare lymphoma.

✅ In June 2025, SGR-1505, a non-covalent BTK inhibitor, received US FDA fast track designation for patients with relapsed/refractory Waldenstrom macroglobulinemia following at least two prior therapies. Early clinical data shows promising safety and efficacy, advancing treatment options in WM management.

Japan: Recent Industry Developments

✅ In September 2025, zanubrutinib demonstrated high response rates and durable responses among Japanese patients with Waldenstrom macroglobulinemia in clinical use. This BTK inhibitor continues to gain traction as a preferred targeted therapy in Japan's WM patient population.

✅ In 2025, tirabrutinib remains the only BTK inhibitor launched and marketed clinically exclusively in Japan for WM. Clinical experience shows it has fewer off-target effects and favorable outcomes, especially for complex cases involving renal dysfunction.

✅ In June 2025, a study using droplet digital PCR for the MYD88 L265P mutation in Japanese WM patients highlighted its prognostic importance as a tumor burden marker. This genetic testing advances personalized NM diagnosis and treatment strategies in Japan.

✅ In 2025, Japanese clinical practice includes successful management of WM patients with nephrotic syndrome and renal failure using tirabrutinib combined with hemodialysis, showcasing innovation in complicated WM cases and improved patient outcomes.

Waldenstrom Macroglobulinemia Market: Drivers

The Waldenstrom macroglobulinemia (WM) treatment market is growing due to rising awareness and improved diagnosis of this rare, slow-growing blood cancer affecting B lymphocytes. Targeted therapies, including Bruton's tyrosine kinase (BTK) inhibitors and monoclonal antibodies, are enhancing patient outcomes by reducing tumor burden and managing symptoms such as hyperviscosity and anemia. Advances in precision medicine and personalized treatment approaches are supporting better disease management and improving quality of life. Increasing clinical research and ongoing trials for novel therapies are expanding treatment options. The availability of oral therapies with manageable safety profiles is further encouraging patient adherence and market growth.

Rising investments in hematology research and rare disease therapies are fueling the development of innovative WM treatments. Expansion of specialty oncology clinics and improved access to diagnostic and therapeutic services are boosting adoption. Regulatory support for orphan drugs and accelerated approval pathways encourages pharmaceutical innovation. Growing awareness among healthcare providers and patient communities about early diagnosis and treatment options is driving demand. With continuous clinical advancements and focus on targeted therapies, the Waldenstrom macroglobulinemia treatment market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/waldenstrom-macroglobulinemia-market?sp

Waldenstrom Macroglobulinemia Market: Major Players

AbbVie, BeiGene, Amgen, TG Therapeutics, Gilead Sciences, Acerta Pharma BV, Johnson & Johnson Services, Inc, Novartis AG, Seattle Genetics, Inc, Merck & Co., Inc, Xiamen Research Biotechnology Co., Ltd, Shanghai Synchem Pharma Co., Ltd, Shanghai Hanjing Chemicals Co., Ltd, Shenzhen Excellent Biotech Co., Ltd.

Segment Covered in the Waldenstrom Macroglobulinemia Market:

➥ By Treatment Type: Standard Treatment, Advance Treatment

➥ By Drugs: Ibrutinib, Rituximab, Venetoclax, Umbralisib, BGB-3111, Acalabrutinib, Zydelig, Oprozomib

➥ By Route of Administration: Oral, Parenteral

➥ By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

Research Process:

Both primary and secondary data sources have been used in the Waldenstrom Macroglobulinemia Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Waldenstrom Macroglobulinemia Market Research Industry:

➠ Who leads the Waldenstrom Macroglobulinemia industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Waldenstrom Macroglobulinemia market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Waldenstrom Macroglobulinemia market growth?
➠ What are the dominant sales and distribution strategies in the Waldenstrom Macroglobulinemia industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=waldenstrom-macroglobulinemia-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.